Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Top 100 Creative Companies

- PMLiVE

ICER says Alnylam’s Onpattro should cost 90%-95% less

Even after discounts the medication exceeds the cost-effectiveness threshold

Pitch Perfect

What makes a perfect pitch? This week’s Thirsty Thursday – hosted by Louise Verrall, a managing director at Lucid Partners – was all about just that.Louise started her session with an involved...

Lucid Group Communications Limited

Roche Basel Switzerland

Affimed rockets on $5bn-plus Roche immuno-oncology deal

Deal is latest in series of big pharma investments in cancer immunotherapies

- PMLiVE

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

The latest from pharma, biotech and healthcare

- PMLiVE

Brexit medicine stockpiling could cost £2bn

Cost will be incurred whether a 'no deal' Brexit is avoided or not

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

BMS appoints new commercial leader, Davies joins Eisai and more

The latest industry movers

- PMLiVE

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

FDA rejects Waylivra, Roivant group continues gene therapy drive, UK biotech gains £637k

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

Roche Diagnostics’ chief heads for the exit

No surprise if Diggelmann resurfaces at diagnostics start-up or rival

- PMLiVE

It’s a no for Yescarta, says NICE on heels of EU approval

Gilead gets rapid knock-back from cost effectiveness watchdog

- PMLiVE

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

Drug increased PFS by 2.6 months compared to Pfizer’s Sutent

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links